Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)
Retrospective analysis shows similar overall survival in DDX41-mutated AML treated with hypomethylating agent/venetoclax or intensive chemotherapy, suggesting both are viable options.
Key Points
This research compares the outcomes of DDX41-mutated acute myeloid leukemia patients treated with intensive chemotherapy versus hypomethylating agent/venetoclax.
Retrospective review of AML patients diagnosed at Moffitt Cancer Center between 9/2017 and 3/2025.
Inclusion of patients with DDX41 mutations on next generation sequencing receiving upfront therapy.
Survival analysis through Kaplan-Meier and Cox proportional hazards modeling.
51 patients analyzed (21 IC, 30 HMA/VEN), showing median overall survival of 40 months overall.
Older age correlates with worse overall survival, and allo-HCT is linked to better outcomes.
Treatment responses and survival outcomes were comparable between the two therapeutic approaches.